Ginkgo Bioworks Holdings, Inc.
NYSE:DNABiotechnology
+$0.26 today
- Market cap
- $547.12M
- Beta
- 1.80
- P/E (TTM)
- -1.7
- EPS (TTM)
- -$5.11
Volume 2.36M
Average 1.24M
DNA Retained Earnings
Cumulative profits kept in the business rather than paid out as dividends.
Ginkgo Bioworks Holdings, Inc.NYSE: DNA
Retained Earnings · Q1 FY2026 · quarter ended Mar 2026
Retained earnings remains negative
Q1 FY2026 retained earnings was -$6.23B, compared with -$5.93B a year earlier.
Context
- Retained earnings amounted to 603.3% of total assets at the end of Q1 FY2026, up 145.0 pp from a year earlier.
- Retained earnings grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether retained earnings keeps falling in the next quarterly balance sheet after a -5.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Retained Earnings history
USD · from the balance sheet
- Latest · FY2025
- (6.15B) USD
- Year-over-year change
- -5.4%
| Period | Period end | Retained Earnings | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (6.15B) | -5.4% |
| FY2024 | 2024-12-31 | (5.84B) | -10.3% |
| FY2023 | 2023-12-31 | (5.29B) | -20.3% |
| FY2022 | 2022-12-31 | (4.4B) | -91.4% |
| FY2021 | 2021-12-31 | (2.3B) | — |
Retained Earnings vs competitors
How DNA compares with its peers on the latest reported figures
- Peers report in different currencies, so retained earnings is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -5.1% is the highest of 10, against a peer median of -36.0%.
- Retained earnings amounts to 603.3% of total assets for DNA, versus a peer median of 191.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | -$6.03M USD | -108.5% | -70.8% | 1.0% | |
MBXMBX Biosciences, Inc. Common Stock | Sep 2026 | -$347.51M USD | -71.7% | — | 69.4% |
| Mar 2026 | -$447.96M USD | -48.0% | — | 128.2% | |
| Mar 2026 | -€711.94M EUR | -24.2% | — | 191.2% | |
| Mar 2026 | -$862.54M USD | -16.2% | — | 352.6% | |
| Dec 2025 | -$1.19B USD | -36.0% | — | 356.5% | |
| Mar 2026 | -$1.32B USD | -50.3% | — | 129.0% | |
| Mar 2026 | -$1.67B USD | -15.3% | — | 257.9% | |
| Sep 2026 | -$2.92B USD | -8.2% | — | 295.0% | |
| Mar 2026 | -$6.23B USD | -5.1% | — | 603.3% | |
| Peer median (excluding DNA) | — | -36.0% | -70.8% | 191.2% | |
Competitors are the stored peer set for DNA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 1.55B | 1.32B | 944.07M | 561.57M | 167.2M |
| Short-term Investments | 0 | 0 | 0 | 0 | 255.42M |
| Net Receivables | 149.9M | 84.03M | 17.9M | 22.44M | 24.03M |
| Inventory | 3.36M | 4.36M | 46K | 0 | 0 |
| Other Current Assets | 698K | 8.71M | 18.99M | 18.73M | 25.19M |
| Total Current Assets | 1.72B | 1.45B | 1B | 602.74M | 471.84M |
| Property, Plant & Equipment (Net) | 145.77M | 718.79M | 394.99M | 598.16M | 528.7M |
| Goodwill | 21.31M | 60.21M | 49.24M | 0 | 0 |
| Intangible Assets | 21.64M | 111.04M | 82.74M | 72.51M | 56.92M |
| Long-term Investments | 115.23M | 111.79M | 77.91M | 48.7M | 15.07M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 43.99M | 87.41M | 58.71M | 55.34M | 47.17M |
| Total Non-current Assets | 347.95M | 1.09B | 663.59M | 774.71M | 647.86M |
| Total Assets | 2.07B | 2.54B | 1.67B | 1.38B | 1.12B |
| Account Payables | 8.19M | 10.45M | 9.32M | 14.17M | 10.57M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 33.24M | 47.82M | 48.5M | 30.6M | 19.98M |
| Other Current Liabilities | 40.31M | 52.51M | 54.38M | 26.62M | 32.12M |
| Total Current Liabilities | 134.76M | 172.96M | 163.86M | 107.27M | 95.97M |
| Long-term Debt | 0 | 0 | 0 | 0 | 417.08M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 155.99M | 174.77M | 158.06M | 98.78M | 0 |
| Other Non-current Liabilities | 190.58M | 42.06M | 24.43M | 16.58M | 98.06M |
| Total Non-current Liabilities | 368.85M | 630.08M | 404.33M | 554.13M | 515.14M |
| Total Liabilities | 503.61M | 803.04M | 568.19M | 661.39M | 611.11M |
| Common Stock | 161K | 190K | 5K | 5K | 6K |
| Retained Earnings | (2.3B) | (4.4B) | (5.29B) | (5.84B) | (6.15B) |
| Accumulated OCI | (1.72M) | (2.63M) | 1.48M | (1.81M) | 1.85M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 62.01M | 0 | 0 | 0 | 0 |
| Total Equity | 1.57B | 1.74B | 1.1B | 716.06M | 508.59M |
| Total Debt | 23.03M | 442.59M | 239.31M | 467.73M | 439.89M |
| Net Debt | (1.53B) | (873.2M) | (704.76M) | (93.84M) | 272.68M |
Ginkgo Bioworks Holdings, Inc.
NYSE:DNA
Intrinsic Alpha fair value
Locked
Current Price
$8.44
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.